Dosing & Uses
Dosage Forms & Strengths
Discontinued by manufacturer (12/18/2012)
Indicated preoperatively and/or postoperatively for iridocyclitis
Instill 1-2 gtt into eye(s) up to 4 times/day
Mydriasis & Cycloplegia
Indicated in diagnostic procedures
Instill 1-2 gtt into eye(s) 1 hr before refracting
Avoid excessive absorption by compressing lacrimal sac with fingers for 2-3 minutes after instillation
Safety and efficacy not established
Frequency Not Defined
Excessive use may cause systemic effects (eg, somnolence, drowsiness, visual hallucinations)
Increased intraocular pressure
Primary glaucoma or narrow anterior chamber angle
Do not touch dropper to avoid contamination; contaminated multi-dose solutions may cause bacterial keratitis
Estimate depth anterior chamber angle to avoid inducing angle-closure glaucoma
Initial visual disturbances and pain within the eye are reasons for discontinuation
Ophthalmic use only
Remove contact lenses prior to administration and wait 15 min before reinserting
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Distributed in breast milk; American Academy of Pediatrics classifies scopolamine as compatible with breast-feeding
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Elicits anticholinergic effects at parasympathetic sites in sphincter muscle of the iris and accommodative muscle of the ciliary body; prevents accomodation and dilates pupils